Fig. 4: Kdm4b knockout decreases cGAS-mediated anti-virus in vivo.
From: KDM4B enhances immune surveillance via demethylating cGAS
A Timeline for HSV-1 treatment in the indicated mice. B Kaplan–Meier (KM) analyses of the survival in the Kdm4b KO and WT mice treated with HSV. Mice were infected with 1 × 106 pfu HSV for 4 days. The survivals were monitored for 8 days. P values were obtained from the log-rank test. n = 6 mice. C Type I IFN expression including lfnb1, Cxcl10, and Il6 were detected in the lung from the Kdm4b KO and WT mice treated with HSV for 1 day. D and E Type I IFN expression including lfnb1, lfna4 and Il6 were detected in the spleen (D) and heart (E) from the Kdm4b KO and WT mice treated with HSV for 4 days. F Proposed working model of KDM4B on cGAS–STING signaling and related diseases. Data are mean ± SEM for C–E, unpaired t test. *P < 0.05, **P < 0.01, ns, not significant.
